Derm Q&A

Steven R. Cohen, MD, MPH, met with The Dermatologist to discuss the efficacy of high dose intralesional triamcinolone (ILTAC) for hidradenitis suppurativa.

New therapies for actinic keratosis, such as a novel ointment currently in being tested in clinical trials, may offer alternative options for treatments of precancerous lesions.

In this Q&A, Dr Yosipovitch speaks about the relationship of pain and AD, how to consider pain in these patients, and what therapies may be successful in treating AD-related pain.

Jonathan Silverberg, MD, spoke with The Dermatologist regarding recent research into pain as a symptom of atopic dermatitis (AD) and how dermatologists can evaluate AD-related pain within clinical practice.

Historically, patient care has been determined by the physician, leaving patients out of critical decisions that can affect their overall health. Involving patients with psoriasis in their care plan may see improved health and satisfaction outcomes.

What’s on the horizon for the treatment of urticaria? Is there an association between urticaria and COVID-19? Dr Brian Berman answers these questions and more in this one-on-one interview.

Dr Arendt-Nielsen details the similarities and differences in the pathophysiology of itch and pain, highlighting the need for more research to better understand their relationship.

At the 2020 Fall Clinical Dermatology Conference, Anthony J. Mancini, MD, reviewed treatment options for warts and MC. He discussed this approach to treating these conditions and shared clinical pearls in an interview with The Dermatologist.

Findings from a phase 2b clinical trial showed delgocitinib was effective for atopic dermatitis. Margitta Worm, MD, discussed these findings and their implications in an interview with ALN.

Whitney High, MD, discussed malpractice concerns during the COVID-19 pandemic at Fall Clinical 2020 and shared his notes in an interview with The Dermatologist.